AstraZeneca Sees Prilosec OTC As “Neutral To Beneficial” For Nexium Sales
This article was originally published in The Tan Sheet
Executive Summary
The effect Prilosec OTC has on health plan formularies may provide an upshot for sales of AstraZeneca's follow-on Nexium (esomeprazole), CFO Jonathan Symonds said during an Oct. 23 earnings call
You may also be interested in...
Generic PPIs Look For Long-Term Formulary Benefit From Prilosec OTC
Price pressures caused by the availability of Procter & Gamble's Prilosec OTC may offer potential upsides for generic omeprazole offerings regarding favorable formulary status, according to insurers
Generic PPIs Look For Long-Term Formulary Benefit From Prilosec OTC
Price pressures caused by the availability of Procter & Gamble's Prilosec OTC may offer potential upsides for generic omeprazole offerings regarding favorable formulary status, according to insurers
Generic PPIs Look For Long-Term Formulary Benefit From Prilosec OTC
Price pressures caused by the availability of Procter & Gamble's Prilosec OTC may offer potential upsides for generic omeprazole offerings regarding favorable formulary status, according to insurers